10-Q: Philip Morris International Reports Strong Q2 Earnings Driven by Smoke-Free Growth Amidst Legal Challenges

Philip Morris International announced robust second-quarter and first-half 2025 financial results, fueled by significant growth in its smoke-free product portfolio, despite ongoing litigation and geopolitical headwinds.

Summary

• Net revenues for the six months ended June 30, 2025, increased by 6.5% to $19.441 billion, and by 7.1% to $10.140 billion for the three months, primarily driven by favorable pricing and smoke-free product volume.
• Diluted earnings per share (EPS) for the six months ended June 30, 2025, rose by 25.7% to $3.67, and by 26.6% to $1.95 for the three months, benefiting from higher operating income, a lower effective tax rate, and increased income from equity investments.
• Smoke-free product net revenues grew by 15.1% to $8.055 billion for the six-month period and by 15.2% to $4.161 billion for the three-month period.
• Heated Tobacco Unit (HTU) shipment volume increased by 10.5% to 75.899 billion units for the six months and by 9.2% to 38.810 billion units for the three months.
• Oral Smoke-Free Product (SFP) volume surged by 28.8% to 626.3 million cans for the six months and by 26.5% to 308.4 million cans for the three months, largely driven by ZYN nicotine pouches in the U.S.
• Cigarette shipment volume saw a slight decrease of 0.3% to 300.001 billion units for the six months and a 1.5% decrease to 155.248 billion units for the three months.
• Operating income increased by 11.8% to $7.256 billion for the six months and by 7.8% to $3.712 billion for the three months, though partially offset by higher marketing, administration, and research costs, restructuring charges, goodwill impairment, and amortization of intangibles.
• Net cash provided by operating activities for the first six months of 2025 was $3.062 billion, a decrease from $4.873 billion in the comparable 2024 period, primarily due to higher working capital requirements and tax payments, including a $0.8 billion payment for the German HTP supplemental tax surcharge.
• The company recorded a goodwill impairment charge of $41 million in the second quarter of 2025 related to a reporting unit in the Europe segment.
• Restructuring charges of $243 million were recorded in the second quarter of 2025, primarily due to the cessation of combustible tobacco production in two German factories.
• Total debt increased to $51.5 billion at June 30, 2025, from $45.7 billion at December 31, 2024, mainly due to higher net borrowings, including commercial paper.

Sentiment

Score: 8

Explanation: The company demonstrates strong financial performance with significant growth in net revenues, operating income, and EPS, largely driven by the successful expansion of its smoke-free product portfolio. Key regulatory authorizations for ZYN and IQOS in the U.S. are positive milestones. However, the company faces substantial and growing litigation risks related to its oral nicotine products, ongoing geopolitical uncertainties in Russia and Ukraine, and a decrease in operating cash flow due to working capital and tax payments. The overall outlook is positive due to strategic execution, but tempered by these material risks.

Positives

• Strong growth in smoke-free product net revenues, increasing by 15.1% for the six months and 15.2% for the three months.
• Significant increase in Heated Tobacco Unit (HTU) shipment volume by 10.5% for the six months and 9.2% for the three months.
• Oral Smoke-Free Product (SFP) volume, particularly ZYN nicotine pouches in the U.S., showed robust growth of 28.8% for the six months and 26.5% for the three months.
• Diluted EPS increased substantially by 25.7% for the six months and 26.6% for the three months, driven by operational improvements, lower effective tax rate, and higher equity investment income.
• Operating income saw healthy growth of 11.8% for the six months and 7.8% for the three months.
• FDA authorized 20 ZYN nicotine pouch varieties for sale in the U.S. on January 16, 2025, and renewed General snus modified risk orders on November 7, 2024, until November 2032.
• PMI began selling IQOS 3.0 in Austin, Texas, on March 27, 2025, marking its re-entry into the U.S. market with its heat-not-burn product.
• Interest expense, net, decreased by 17.5% for the six months and 15.8% for the three months, primarily due to a lower weighted average cost of debt and favorable derivative financial instruments.
• The effective tax rate decreased to 19.5% for the six months and 19.0% for the three months, favorably impacted by a deferred tax benefit related to Swedish Match acquisition financing.
• Income from equity investments and securities, net, increased significantly by 65.1% for the six months and over 100% for the three months, driven by favorable fair value adjustments for investments in India and Sri Lanka.

Negatives

• Net cash provided by operating activities decreased by $1.811 billion for the six months ended June 30, 2025, compared to the prior year, primarily due to higher working capital requirements and increased tax payments.
• Cigarette shipment volume experienced a slight decline of 0.3% for the six months and 1.5% for the three months, reflecting the ongoing shift away from combustible products.
• A goodwill impairment charge of $41 million was recorded in the Europe segment during the second quarter of 2025.
• Restructuring charges of $243 million were incurred in the second quarter of 2025 due to the closure of two combustible tobacco production factories in Germany.
• Marketing, administration, and research costs increased, partly offsetting the gains from favorable pricing and volume/mix.
• The company's total debt increased to $51.5 billion at June 30, 2025, from $45.7 billion at December 31, 2024.
• The unfavorable currency impact on net revenues was primarily due to the Euro, Indonesian rupiah, Japanese yen, and Mexican peso for the six-month period.

Risks

• Regulatory restrictions on products, including bans or severe limitations on smoke-free products (SFPs) and communication of scientifically substantiated information, could reduce competitiveness or ban products.
• Fiscal challenges such as excessive excise tax increases and discriminatory tax structures could adversely impact profitability and encourage illicit trade.
• Ongoing and potential future litigation related to tobacco and nicotine products, including class actions and health care cost recovery cases, could substantially reduce profitability and impair liquidity.
• Specific litigation risks include ZYN nicotine pouch lawsuits in the U.S. alleging addiction, defective design, and marketing to minors, as well as an antitrust lawsuit.
• Geopolitical developments, particularly the continuation and consequences of the war in Ukraine, could adversely impact business, results of operations, cash flows, and financial position, including potential material impairment of Russian assets ($4.3 billion total assets, $1.8 billion cash in local currency).
• Economic factors such as sustained elevated inflation could lead to higher operating and financing costs and reduced demand for products.
• Supply chain disruptions, reliance on third-party manufacturers (e.g., ZYN production facility in Kentucky), and the effects of climate change on agricultural products (tobacco leaf, cloves) could negatively impact product availability, quality, and costs.
• Inability to adequately protect intellectual property rights or disputes relating to intellectual property rights could harm the business.
• Intense competition, including from lower-price products, non-tax-paid volume, and new market entrants, could adversely affect profitability.
• Failure to anticipate changes in adult consumer preferences or to successfully introduce new products and expand market positions could limit profit growth.
• The research, development, and commercialization of non-recreational cannabinoid products subject the company to legal, regulatory, and reputational risks.
• Changes in the earnings mix and changes in tax laws, including the OECD's Pillar Two framework and punitive tax legislation related to Russia, may result in significant variability in effective tax rates.
• Capital controls or foreign currency exchange constraints in certain markets (e.g., Argentina, Russia) could restrict the ability of subsidiaries to convert local currency or pay dividends/royalties, increasing devaluation risks.
• Cybersecurity incidents or attacks on information technology networks and systems could lead to business disruption, data breaches, reputational damage, litigation, and financial penalties.

Future Outlook

For the full year 2025, PMI expects estimated total international industry volume for cigarettes and HTUs (excluding China and the U.S.) to decline by around 1%. Total cigarette and smoke-free product shipment volume growth for PMI is anticipated to be around 1%, with smoke-free product volume growth projected at 12% to 14%, partly offset by cigarette volume declines of approximately 2%. Modest declines for total PMI volumes are possible in the second half of 2025 due to cigarette dynamics. HTU adjusted in-market sales growth is expected to be 10% to 12% for the year, with growth skewed to the fourth quarter. U.S. nicotine pouch shipment volume is forecast to be 800 million to 840 million cans, including a sequential step-up in the fourth quarter. The 2025 effective tax rate is estimated to be approximately 22% to 23%, excluding discrete tax events. Net cash provided by operating activities for the full year 2025 is expected to be around $11.5 billion, and total capital expenditures are projected to be around $1.6 billion, almost entirely for the smoke-free business. The global tariff environment is expected to remain volatile throughout 2025.

Management Comments

• We recognize that smoking cigarettes causes serious diseases and that the best way to avoid the harm of smoking is to never start or to quit.
• For adult smokers who would otherwise continue to smoke cigarettes, we believe that SFPs, while not risk-free, offer a much better choice.
• We advocate for regulatory frameworks that are based on a continuum of risk where non-combustible products fall below combustible cigarettes.
• We believe that regulation and taxation should differentiate between cigarettes and products that present, are likely to present, or have the potential to present less risk of harm to adult smokers who switch to these products versus continued smoking.
• We support mandated accurate and factual health warnings on packaging, minimum age laws, restrictions on advertising, and smoking restrictions in public spaces.
• We oppose excessive or prohibitive regulations that may prevent adult smokers, who would otherwise continue smoking, from accessing and switching to SFPs or trigger unintended consequences such as illicit trade.
• Our fundamental view remains that we do not expect a meaningful long-term change in the structural growth of the category [heated tobacco products in EU despite flavor ban].
• We currently believe we are well-positioned to mitigate potential supply chain challenges and that the changing tariff environment will not have a material impact on our business.
• In Ukraine, our main priority remains the safety and security of our employees and their families in the country.
• We are continuously assessing the evolving situation in Russia, including regulatory constraints in the market entailing very complex terms and conditions that must be met for any divestment transaction to be granted approval by the authorities, and restrictions resulting from international regulations.
• We expect that the combination of our long-term and short-term debt financing, the commercial paper program and the committed credit facilities, coupled with our operating cash flows, will enable us to meet our liquidity requirements.

Industry Context

The tobacco industry continues its global transformation, with a significant shift from combustible cigarettes to smoke-free products (SFPs). PMI is actively leading this transition, investing heavily in the development and commercialization of heat-not-burn (IQOS), e-vapor (VEEV), and oral nicotine (ZYN) products. The regulatory landscape remains highly dynamic and inconsistent, with some jurisdictions embracing harm reduction while others impose bans or severe restrictions on SFPs. The World Health Organization's Framework Convention on Tobacco Control (FCTC) continues to influence global tobacco regulation, often advocating for stricter measures. The industry also faces persistent challenges from illicit trade, which is now increasingly targeting SFPs, and macroeconomic pressures such as inflation and volatile tariff environments. PMI's strategy aligns with the broader industry trend of diversifying away from traditional tobacco, but it navigates a complex environment of evolving consumer preferences, intense competition, and significant legal and geopolitical risks.

Comparison to Industry Standards

• PMI's cigarette brands hold the number one or number two market share position in many of its approximately 170 markets, indicating a strong competitive standing in the traditional tobacco segment.
• Swedish Match's ZYN is identified as the leading nicotine pouch brand in the U.S. market, positioning PMI at the forefront of the modern oral nicotine category.
• PMI's IQOS devices and consumables, along with Swedish Match's General snus and ZYN nicotine pouches, have received the first-ever marketing and Modified Risk Tobacco Product (MRTP) authorizations from the U.S. FDA in their respective categories, setting a benchmark for scientific substantiation in the industry.
• The company's HTU adjusted in-market sales volume growth of 19.8% in SSEA, CIS & MEA and 9.6% in EA, AU & PMI GTR for Q2 2025 demonstrates strong performance in the heated tobacco segment compared to the broader industry trend of continued HTU growth.
• PMI's advocacy for science-based regulatory frameworks that differentiate between combustible and non-combustible products aligns with a progressive segment of the industry seeking to maximize adult smoker switching to less harmful alternatives.

Management Changes

Corporate Governance

Legal Proceedings

• **Canadian Tobacco Litigation**: Ongoing class actions (Blais, Ltourneau, Kunta, Adams, Semple, Dorion, McDermid, Bourassa, Jacklin) and health care cost recovery cases (10 provinces) against Rothmans, Benson & Hedges Inc. (RBH) and other defendants. A comprehensive plan of compromise and arrangement was approved by the CCAA court on March 6, 2025, for an aggregate global settlement amount of CAD 32.5 billion (approximately $23.7 billion), to be funded by RBH through upfront and annual payments based on net after-tax income.
• **U.S. ZYN Nicotine Pouch Litigation**: Multiple lawsuits filed, including putative class actions (Kelly, Bates-Ferreira, Norris) and individual complaints (Palmer, Lendinara, Friedman), alleging nicotine addiction, defective product design, marketing to minors, misrepresentation, and fraud. The Mayor and City Council of Baltimore also filed a case alleging deceptive marketing. Cases are in various stages of discovery, with some consolidated or stayed.
• **Antitrust Litigation (U.S.)**: A putative class action (Neumark v. Swedish Match North America LLC) alleges violations of federal and state antitrust laws, claiming an anticompetitive agreement with PMI following the Swedish Match acquisition. A motion to dismiss is pending.
• **Thailand Customs Duties Case**: Philip Morris (Thailand) Limited faces charges for alleged underpayment of customs duties and excise taxes (2000-2003). A fine of approximately THB 130 million (approximately $4 million) was imposed and paid in April 2020. Appeals to the Supreme Court of Thailand are pending regarding the fine amount and dismissal of charges against an individual defendant.
• **Italy Anti-Corruption Investigation**: Philip Morris Italia S.r.l. and individuals are under preliminary investigation for alleged contravention of anti-corruption laws and disruption of trade freedom (2018). Trial commenced on September 25, 2023, and is expected to continue in 2025. British American Tobacco Italia S.p.a. is seeking EUR 50 million (approximately $58 million) in damages.
• **Brazil Indirect Tax Assessments**: The Brazilian Tax Authority issued assessments alleging underpayments of indirect taxes for 2020 and 2021, totaling approximately BRL 348 million (approximately $64 million). The affiliate disputes these assessments.
• **Germany Heated Tobacco Product (HTP) Excise Tax Classification**: Philip Morris (Germany) GmbH is challenging the classification of TEREA consumables as cigarettes for excise tax purposes. An associated tax assessment of EUR 151 million (approximately $176 million) was paid in April 2025. The Fiscal Court in Düsseldorf referred two questions to the European General Court regarding EU tax laws.
• **Japan Patent Infringement Actions**: Future Technology K.K. (FTKK) filed multiple patent infringement actions against Sojitz Corporation (PMJL's importer and distributor) regarding TEREA and SENTIA consumables, seeking damages and preliminary injunctions. PMJL is obligated to indemnify Sojitz and is vigorously defending these matters. Tokyo Customs rejected one import injunction request.

Related Party Transactions

• Net revenues from related parties totaled $2,080 million for the six months ended June 30, 2025, and $1,143 million for the three months ended June 30, 2025.
• Trade receivables from related parties amounted to $1,026 million as of June 30, 2025.
• Payables to related parties amounted to $93 million as of June 30, 2025.
• PMI holds a 23% equity interest in JSC TK Megapolis, its distributor in Russia, with a carrying value of $319 million as of June 30, 2025.
• PMI holds a 49% equity interest in Emirati Investors-TA (FZC) (EITA) and an approximate 25% economic interest in Socit des Tabacs Algro-Emiratie (STAEM).
• PMI acquired a controlling interest of 54.25% in United Tobacco Company (UTC) in Egypt in May 2024, finalizing measurement period adjustments in May 2025.
• PMI acquired an indirect economic interest of 14.7% in Eastern Company (Egypt) in May 2024 and guaranteed certain credit facilities and repayment of bank loan liabilities up to $385 million until 2034.
• Transactions with related parties primarily involve distribution, service fees, contract manufacturing, and license agreements.

Stakeholder Impact

• **Shareholders**: Experienced increased diluted EPS and an approved quarterly dividend increase to $1.35 per common share ($5.40 annualized), indicating favorable returns. However, they face potential risks from ongoing litigation, geopolitical instability, and currency fluctuations.
• **Employees**: Impacted by restructuring activities, including the cessation of combustible tobacco production in Germany, which involved pension and employee separation costs. The company prioritizes the safety and security of employees in Ukraine. Management compensation adjustments, such as Stacey Kennedy's grade increase and stock award target, reflect internal talent management.
• **Customers**: Benefit from the expansion of smoke-free product availability in 97 markets and the re-entry of IQOS into the U.S. market. However, regulatory restrictions in some markets may limit product access or information.
• **Suppliers**: Participate in a voluntary supply chain financing program. Some suppliers may face disruptions due to geopolitical events or tariffs, though PMI aims to mitigate these impacts.
• **Creditors**: The company's total debt increased, but it maintains access to global credit markets and committed revolving credit facilities, indicating continued liquidity and ability to meet obligations. Credit ratings remain stable.

Next Steps

• The appeal ruling on the legality of the supplemental tax surcharge on heated tobacco products in Germany is expected in or after September 2025.
• The Tobacco Product Scientific Advisory Committee (TPSAC) will hold a meeting on PMI's IQOS MRTP renewal application on October 7, 2025.
• The Eleventh session of the Conference of the Parties (CoP) to the FCTC is scheduled for November 2025.
• The Third Meeting of the Parties to the Protocol to Eliminate Illicit Trade in Tobacco Products is scheduled for November 2025, with further work on a mandate to be considered.
• The Canadian CCAA Plan for tobacco claims is expected to be implemented and become effective sometime in the second half of 2025.
• The deadline for the completion of all fact and expert discovery in the consolidated Florida ZYN cases (Kelly, Palmer, Lendinara, and Friedman) is June 26, 2026.
• The trial for the consolidated Florida ZYN cases is set to begin on December 7, 2026.
• The first step of excise tax harmonization for heated tobacco products with cigarettes in Japan will occur on April 1, 2026, followed by the second step on October 1, 2026.
• The first increase in the harmonized HTP and cigarette excise tax in Japan will occur in April 2027.
• The proposed implementation date for the revised EU Tobacco Excise Directive is January 1, 2028.
• PMI anticipates making additional contributions of approximately $102 million to its pension plans during the remainder of 2025.
• PMI will continue to monitor developments in the global tariff environment throughout 2025 and new sanctions and other trade laws to ensure full compliance.
• PMI is currently evaluating the impact of ASU 2023-09 on its disclosures.

Key Dates

Recommendation

Philip Morris International demonstrates strong operational performance, particularly in its strategic shift towards smoke-free products, which are driving significant revenue and EPS growth. The company's re-entry into the U.S. IQOS market and FDA authorizations for ZYN are positive catalysts. However, the company faces substantial and escalating litigation risks related to its oral nicotine products in the U.S., which could lead to significant financial liabilities and reputational damage. Ongoing geopolitical uncertainties, especially concerning its Russian operations, and a decrease in operating cash flow due to working capital and tax payments, introduce additional layers of risk. While the long-term transformation strategy is compelling, these material uncertainties warrant a cautious 'hold' stance for seasoned investors, suggesting monitoring developments closely before making further investment decisions.

Keywords

Tobacco, Smoke-free products, IQOS, ZYN, Nicotine pouches, Heated tobacco, E-vapor, SEC filing, Quarterly report, Financial results, Earnings, Revenue, EPS, Litigation, Regulatory risk, Geopolitical risk, Supply chain, Market share, Transformation, Consumer goods